EXTON, PA (Sept. 20, 2004) – Antares Pharma, Inc., a specialty pharmaceutical company, announced that its common stock has been approved, subject to compliance with applicable standards, for listing on the American Stock Exchange (Amex).
Antares Pharma’s common stock is expected to begin trading on Amex under the symbol “AIS,” effective September 23.
“We … believe our Amex listing will expand our shareholder base by facilitating participation in our stock by brokers and institutional investors, resulting in increased liquidity and value for all of our shareholders,” Jack E. Stover, Antares president and chief executive officer, said, “Our listing on Amex … is a significant milestone and we anticipate that it will provide greater visibility and broader exposure of Antares Pharma’s stock.
September 22 is expected to be the last trading date for Antares Pharma common stock on the over-the-counter Bulletin Board, the company said.
